Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

Publication Type:

Journal Article


The lancet oncology, Volume 11, Issue 6, p.543-52 (2010)


2010, Adolescent, Aminoglycosides, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Center-Authored Paper, Child, Child, Preschool, Clinical Research Division, Cytarabine, Cytogenetic Analysis, Daunorubicin, Disease-Free Survival, Etoposide, Female, Flow Cytometry Core Facility, Humans, Infant, Infant, Newborn, Leukemia, Myeloid, Acute, Male, Neoplasm, Residual, Remission Induction, Survival Rate, Young Adult


We sought to improve outcome in patients with childhood acute myeloid leukaemia (AML) by applying risk-directed therapy that was based on genetic abnormalities of the leukaemic cells and measurements of minimal residual disease (MRD) done by flow cytometry during treatment.